Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.48 |
| ▸ | HTR2C | P28335 | 13/20 | 0.48 |
| ▸ | HTR2B | P41595 | 6/20 | 0.48 |
| ▸ | KMO | O15229 | 3/20 | 0.38 |
| ▸ | ERN1 | O75460 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962685 | 0.85 | ATM (0.42) | HTR2AHTR2CHTR2BMAPK1 | |
| SCHEMBL3960378 | 0.85 | ATM (0.42) | HTR2AHTR2CHTR2BMAPK1 | |
| SCHEMBL5843328 | 0.83 | HTR2A (0.50) | HTR2AHTR2CHTR2BKMOMAPK1 | |
| SCHEMBL5637628 | 0.83 | HTR2A (0.50) | HTR2AHTR2CHTR2BKMOMAPK1 | |
| SCHEMBL5843663 | 0.83 | HTR2C (0.53) | HTR2AHTR2CHTR2BKMOMAPK1 | |
| SCHEMBL4950336 | 0.82 | HTR2A (0.49) | HTR2AHTR2CHTR2BKMOMAPK1 | |
| SCHEMBL5639490 | 0.82 | HTR2A (0.46) | HTR2AHTR2CHTR2BKMOMAPK1 | |
| SCHEMBL5638272 | 0.80 | HTR2A (0.46) | HTR2AHTR2CHTR2BKMOMAPK1 | |
| SCHEMBL5845487 | 0.80 | HTR2A (0.46) | HTR2AHTR2CHTR2BKMOMAPK1 | |
| SCHEMBL5638269 | 0.80 | HTR2A (0.46) | HTR2AHTR2CHTR2BKMOMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425572-B2 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | ALCON, INC. (CH) | 2008-09-16 | — | — | US | disclosed |
| US-20060122251-A1 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | ALCON, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122251-A1 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | CYP11B2, CYP11B1, PDE3A | HTR2A 3209/4885HTR2C 2047/4885HTR2B 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.